Literature DB >> 3018217

Action at the mu receptor is sufficient to explain the supraspinal analgesic effect of opiates.

F G Fang, H L Fields, N M Lee.   

Abstract

Mu, delta and kappa opiate receptors have been implicated in the production of analgesia. In order to study the relative contributions of these receptor types to supraspinally mediated analgesia, apparent pA2 values and rank order potencies were determined for i.c.v. injected highly selective opioid agonists in the mouse using a thermal nociceptive test. Drugs used included the prototypical mu agonist morphine, putative mu agonists [D-Ala2, N-methyl-Phe4, Gly5-ol] enkephalin and BAM 22P, putative delta agonists [D-Pen2, D-Pen5] enkephalin, [D-Thr2, Thr6, Leu5] enkephalin and [D-Ser2, Leu5, Thr6] enkephalin and the putative kappa agonists [trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl)-cyclohexyl]- benzeneacetamide methane sulfonate hydrate] and Dynorphin A (1-13). We were unable to demonstrate significant analgesic potencies for i.c.v. injected Dynorphin A (1-13) or BAM 22P in the absence of marked behavioral abnormalities. The rank order potency of the remaining compounds studied was found to be: [D-Ala2, N-methyl-Phe4, Gly5-ol] enkephalin greater than [D-Thr2, Thr6, Leu5] enkephalin greater than [D-Ser2, Leu5, Thr6] enkephalin greater than Morphine greater than [D-Pen2, D-Pen5] enkephalin greater than [trans-3, 4-dichloro-N-methyl-N[2-(1-pyrrolidinyl)-cyclohexyl]-benzeneacetamide methane sulfonate hydrate]. Apparent pA2 values of morphine, [D-Ala2, N-methyl-Phe4, Gly5-ol] enkephalin and [D-Pen2, D-Pen5] enkephalin in naloxone antagonism trials did not differ significantly. These results indicate that although both mu- and delta-selective ligands produce potent analgesia, a single receptor (mu) is sufficient to explain the supraspinal effects of opiate drugs.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3018217

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Supraspinal administration of opioids with selectivity for mu-, delta- and kappa-opioid receptors produces analgesia in amphibians.

Authors:  C W Stevens; K S Rothe
Journal:  Eur J Pharmacol       Date:  1997-07-16       Impact factor: 4.432

2.  Up-regulation of mu-opioid receptors in the spinal cord of morphine-tolerant rats.

Authors:  Subrata Basu Ray; Himanshu Gupta; Yogendra Kumar Gupta
Journal:  J Biosci       Date:  2004-03       Impact factor: 1.826

3.  A new opioid designed multiple ligand derived from the micro opioid agonist endomorphin-2 and the delta opioid antagonist pharmacophore Dmt-Tic.

Authors:  Severo Salvadori; Claudio Trapella; Stella Fiorini; Lucia Negri; Roberta Lattanzi; Sharon D Bryant; Yunden Jinsmaa; Lawrence H Lazarus; Gianfranco Balboni
Journal:  Bioorg Med Chem       Date:  2007-08-29       Impact factor: 3.641

4.  In vivo activation of a mutant mu-opioid receptor by naltrexone produces a potent analgesic effect but no tolerance: role of mu-receptor activation and delta-receptor blockade in morphine tolerance.

Authors:  Sabita Roy; Xiaohong Guo; Jennifer Kelschenbach; Yuxiu Liu; Horace H Loh
Journal:  J Neurosci       Date:  2005-03-23       Impact factor: 6.167

5.  Dual effects of intrathecal BAM22 on nociceptive responses in acute and persistent pain--potential function of a novel receptor.

Authors:  Yanguo Hong; Peifang Dai; Jianping Jiang; Xueai Zeng
Journal:  Br J Pharmacol       Date:  2004-01-12       Impact factor: 8.739

6.  Use of preproenkephalin knockout mice and selective inhibitors of enkephalinases to investigate the role of enkephalins in various behaviours.

Authors:  Florence Noble; Nadia Benturquia; Andras Bilkei-Gorzo; Andreas Zimmer; Bernard P Roques
Journal:  Psychopharmacology (Berl)       Date:  2007-10-01       Impact factor: 4.530

Review 7.  Interactive Mechanisms of Supraspinal Sites of Opioid Analgesic Action: A Festschrift to Dr. Gavril W. Pasternak.

Authors:  Grace C Rossi; Richard J Bodnar
Journal:  Cell Mol Neurobiol       Date:  2020-09-24       Impact factor: 5.046

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.